Research progress on antibody-drug conjugates in the treatment of triple-negative breast cancer
- VernacularTitle:抗体偶联药物在三阴性乳腺癌治疗中的研究进展
- Author:
Danna LIU
1
;
Shuangshuang SONG
2
;
Lu CHEN
2
;
Yongqiang SUN
3
;
Bo SUN
1
;
Hanli ZHOU
2
;
Xiaoli ZHAO
2
;
Tiandong KONG
2
Author Information
1. Dept. of Pharmacy，Cancer Hospital of Henan University （the Third People’s Hospital of Zhengzhou），Zhengzhou 450099，China
2. Dept. of Oncology，Cancer Hospital of Henan University （the Third People’s Hospital of Zhengzhou），Zhengzhou 450099，China
3. Dept. of Breast Cancer Surgery，Cancer Hospital of Henan University （the Third People’s Hospital of Zhengzhou），Zhengzhou 450099，China
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates;
triple-negative breast cancer;
target;
monoclonal antibody;
cytotoxic drugs;
linker
- From:
China Pharmacy
2026;37(1):124-129
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates （ADCs） are a novel class of anti-tumor agents composed of a targeted monoclonal antibody， a cytotoxic drug， and a linker connecting the two. They combine the high specificity of antibodies with the potent cytotoxicity of chemotherapeutic agents. Triple-negative breast cancer （TNBC） is characterized by high aggressiveness， elevated risks of recurrence and metastasis， and poor prognosis， largely due to the lack of effective therapeutic targets. This review summarizes the research progress of ADCs in the treatment of TNBC. It has been found that ADCs targeting human epidermal growth factor receptor 2 （such as trastuzumab deruxtecan）， trophoblast cell surface antigen 2 （such as sacituzumab govitecan and datopotamab deruxtecan）， zinc transporter LIV-1 （such as ladiratuzumab vedotin）， HER-3 （such as patritumab deruxtecan）， epidermal growth factor receptor （such as AVID100）， and glycoprotein non-metastatic melanoma protein B （such as glembatumumab vedotin） have all demonstrated promising therapeutic effects against TNBC. Despite challenges including acquired resistance and treatment-related toxicities， ADCs are undoubtedly reshaping the therapeutic landscape for TNBC and are expected to occupy a more central position in TNBC treatment in the future.
